<DOC>
	<DOCNO>NCT00910676</DOCNO>
	<brief_summary>Patients receive local prophylactic treatment ( Diprosone cream ) 8 week begin EGF-R inhibitor treatment , area body susceptible affected folliculitis .</brief_summary>
	<brief_title>Study About Preventive Treatment Folliculitis Induced Epidermal Growth Factor Receptor Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Folliculitis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Indication Cetuximab patient metastatic colorectal cancer association irinotecan , failure chemotherapy treatment Irinotecan OR Indication Erlotinib , patient metastatic NonSmallCell Lung Carcinoma , failure least one chemotherapy treatment No preexist cutaneous toxicity Contraindication local corticotherapy Previous history severe hypersensibility reaction ( Grade III IV ) due Cetuximab , Irinotecan Erlotinib Betamethasone one excipient product allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>EGF-R inhibitor</keyword>
</DOC>